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Abstract 1 
Primary aldosteronism (PA) comprises subtypes that require different therapeutic strategies. 2 
Adrenal vein sampling (AVS) is recognized by current Endocrine Society guidelines as the only 3 
reliable means to perform the correct subtype diagnosis of PA. Unfortunately, despite being the 4 
“gold standard” procedure, there is no a standardized procedure both in terms of performance and 5 
interpretation criteria. This review addresses several questions that regard clinicians faced with 6 
AVS. For each of these questions we will provide replies based on the available evidence as well as 7 
opinions based on our experience. In particular we will discuss the most appropriate way of 8 
preparing the patient, if it is possible to avoid AVS for some subgroups of patients, the use of 9 
cosyntropin during the procedure, the most appropriate criteria for interpretation of cannulation and 10 
lateralisation, the utility of contralateral “suppression” and finally the strategies to improve success 11 
rates of AVS in centres with limited experience.  12 
  13 
Search strategy 14 
We searched in the Cochrane Library (1993-2014) and in MEDLINE (1959-2014). We used the 15 
search terms "adrenal vein sampling" or "AVS" in combination with the terms "primary 16 
aldosteronism" or "hyperaldosteronism". We selected mainly publications from the past 5 years, but 17 
did not exclude important and highly referenced older publications. We also considered the 18 
reference lists of articles and reviews identified by this strategy and selected the most relevant. 19 
Review articles are cited to provide readers with details and references that are beyond the scope of 20 
this Personal Views article. 21 
 22 
Introduction 23 
Primary aldosteronism (PA) is recognized as the most frequent form of secondary hypertension 24 
accounting for 5% of cases of the general hypertensive population and for 10% of patients referred 25 
to hypertension units (1). Diagnosis and treatment is of particular relevance since PA it is associated 26 
 3 
with a higher risk of cardio- and cerebro-vascular events than essential hypertension (2-4). The 1 
diagnosis of PA comprises three steps, screening, confirmatory/exclusion testing and subtype 2 
diagnosis (5) (specific aspects are reviewed in ref 6-8).  3 
This last step is of fundamental importance to allocate patients to correct management, unilateral 4 
adrenalectomy for aldosterone-producing adenoma (APA) and unilateral adrenal hyperplasia 5 
(UAH) and pharmacotherapy with mineralocorticoid receptor antagonists (MRA) for patients with 6 
bilateral adrenal hyperplasia (BAH) (5). Subtype diagnosis comprises CT scanning and adrenal vein 7 
sampling (AVS).  8 
AVS is a demanding technique, requiring a skilled radiologist; however, for a procedure that is 9 
considered the “gold standard” in PA subtype diagnosis there is a poor reproducibility of the 10 
interpretation of the results between centres due to a lack of standardisation of protocols i.e., 11 
different criteria and protocols are used to define both cannulation of the adrenal veins and 12 
lateralisation of aldosterone production (15,22). This lack of a standardized and widely accepted 13 
AVS protocol used in all centres has meant that some clinicians are reluctant to perform AVS or to 14 
refer patients to centres where this procedure is performed.  15 
In this review we will address several questions that regard clinicians faced with PA subtype 16 
diagnosis and in particular with AVS. For each of these questions we will provide replies based on 17 
available evidence plus opinions based on our experience.  18 
 19 
Subtype diagnosis 20 
First step in subtype diagnosis is the performance of a fine-cuts CT scanning with contrast of the 21 
adrenals which is able to exclude the rare but often fatal aldosterone-producing carcinoma, and 22 
provides anatomical description of the adrenal morphology and often venous drainage. APA are 23 
usually less than 3 cm in diameter and microAPA often less than 1 cm in diameter. MicroAPAs are 24 
not always detectable by CT scanning and sometimes considered part of bilateral nodular 25 
hyperplasia. Similarly, in the case of bilateral nodularity, it is not possible to distinguish between a 26 
 4 
non-functioning adrenal adenoma and an APA, and UAH is frequently undetectable by CT scanning 1 
(5,11). Unfortunately, CT scanning does not provide information about the secretory activity of a 2 
detected nodule and densitometry parameters (Hounsfield units) and contrast wash-out (12) has 3 
proven inadequate to distinguish APA from non-secretory nodules (5). Magnetic resonance is 4 
inferior to CT scanning because its spatial resolution is lower and therefore is a second choice 5 
imaging technique (5).  6 
Following the introduction of AVS in the management of subtype diagnosis of PA (13), many 7 
studies demonstrated the lack of sensitivity and specificity of CT scanning for the detection of 8 
APAs and its ability to distinguish them from non-secretory nodules (11,14-16). Furthermore, the 9 
centralisation of CT scanning to a dedicated radiologist improves sensitivity but does not increase 10 
specificity in the diagnosis of APA (11). Until now, a randomized controlled trial comparing 11 
imaging based decision making versus AVS based decision making with clinical and biochemical 12 
remission of PA as outcome is lacking. Furthermore, the analysis of some APA studies is hampered 13 
by the fact that the removal of the adenoma is not succeeded by immunohistochemical evaluation 14 
and demonstration of biochemical cure of hyperaldosteronism, including post-operative 15 
demonstration of aldosterone suppressibility. 16 
A systematic review of studies that compared imaging techniques and AVS for final PA subtype 17 
diagnosis (using AVS as ‘gold’ standard) included a total of 950 patients (9). If only imaging was 18 
considered, inappropriate adrenalectomy would have occurred in 15% of patients (where AVS 19 
showed bilateral PA), inappropriate exclusion from adrenalectomy would have occurred in 19% 20 
(where AVS showed unilateral PA) and adrenalectomy on the wrong side would have occurred in 21 
4% (where AVS showed aldosterone secretion on the opposite side) (9). 22 
 For these reasons, when adrenalectomy is not contraindicated for concomitant comorbidities and is 23 
desired by the patient, the distinction between unilateral and bilateral PA should be made by AVS 24 
(5,17). 25 
 26 
 5 
Key considerations before AVS 1 
AVS should be performed under no medication that can potentially interfere with the renin-2 
angiotensin system and more specifically that can stimulate renin secretion. For this reason, 1-3 
adrenergic receptor blockers and long-acting calcium channel blockers (preferably non-4 
dihydropyridine, such as verapamil or diltiazem, although dihydropyridine can also be used), which 5 
have no or minimal effects on renin secretion are the preferred drugs to manage blood pressure 6 
before AVS (5,18). If needed, -blockers, angiotensin converting enzyme inhibitors and angiotensin 7 
II receptor blockers can also be used in most cases; in contrast, loop and thiazide diuretics, 8 
amiloride and MRA should be stopped for at least 4-6 weeks before the sampling. A safe measure 9 
to verify that the effect of the drugs on renin levels is lost is to measure renin or plasma renin 10 
activity (PRA) and, if suppressed then AVS can be performed regardless of the time the drug has 11 
been withdrawn. Potassium levels should also be corrected as much as possible (Panel 1). AVS is 12 
best performed early in the morning after at least one hour of recumbency to avoid stimulation of 13 
the renin-angiotensin system on aldosterone secretion thereby potentially reducing the gradient 14 
between adrenal glands. If AVS is performed in the afternoon, similar attention should be taken and 15 
cosyntropin stimulation used to allow correct detection of the cannulation. 16 
 17 
AVS procedure 18 
AVS is performed via a percutaneous femoral vein approach and adrenal veins are commonly 19 
sequentially catheterized under fluoroscopy (Figure 1). The correct position of the catheter is 20 
verified by gentle injection of a small volume (no more than 3 mL) of contrast medium, and blood 21 
is then collected by slow aspiration. Left adrenal vein cannulation is relatively easy to perform since 22 
it generally merges with the inferior phrenic vein to generate a common trunk draining directly into 23 
the left renal vein (19). The shorter and smaller right adrenal vein which usually drains directly into 24 
the inferior vena cava may be difficult to locate and cannulate and to distinguish from other 25 
adjacent small vessels including small hepatic vein branches (19). The difficulty of placing the 26 
 6 
catheter tip within the right adrenal vein and the anatomy of the left adrenal vein that joins the 1 
phrenic vein sometimes causes dilution of the blood: for this reason it is necessary to measure in 2 
each sample both cortisol and aldosterone concentrations. Because cortisol is presumed to be 3 
equally produced by both adrenals of a PA patient, the aldosterone measurement corrected by 4 
cortisol levels in each sample corrects for dilution by non-adrenal blood. Furthermore, cortisol 5 
levels are a measure of correct cannulation of the adrenal veins (Table 1). 6 
The experience and the dedication of the interventional radiologist are fundamental for the success 7 
of the procedure in that centres in which multiple radiologists perform AVS display much lower 8 
success rates of cannulation and higher rates of complications than centres with a dedicated 9 
radiologist (21-23).  10 
 11 
Is it possible to avoid AVS for some subgroups of patients? 12 
According to available guidelines, AVS should be performed in all patients with confirmed PA who 13 
are candidates for adrenalectomy (5,17). Unfortunately, AVS is only available in specialized centres 14 
and therefore, alternative methods that reduce the number of AVS procedures would be attractive 15 
for clinicians. Some centres have observed that in young PA patients (<35-40 years), the presence 16 
of a unilateral nodule (> 10 mm in diameter) and normal appearance of the contralateral adrenal 17 
gland at CT scanning, is always associated with an APA (11,23) (Panel 2). This finding is in 18 
agreement with the observation that non-functioning adrenal adenomas are very rare in young 19 
subjects (24). However, even in young patients the occurrence of incidentalomas is not zero; in a 20 
recent analysis relying on imaging alone in patients with age below 40, this had a specificity of 83% 21 
and a sensitivity of 68% (25). Therefore, the risk of inappropriate adrenalectomy should always be 22 
weighed against the rate of AVS complications in each case and each centre.  23 
Other clinical characteristics have been associated with APA as opposed to BAH (higher 24 
aldosterone and blood pressure levels, lower potassium levels, negative posture test) (23); however, 25 
none of these criteria have proven to be specific enough to avoid performing AVS in an individual 26 
 7 
patient (11,25,26). The [6-131I]iodomethyl-19-norcholesterol (NP-59) scan performed under 1 
dexamethasone suppression, has the potential advantage of correlating function with anatomical 2 
findings. This technique is not available in all countries, is not sensitive enough to detect small 3 
APA and is therefore rarely used (5). Recently, 11C-metomidate positron emission tomography 4 
(PET)-CT scanning has been evaluated for PA subtype diagnosis: the sensitivity (76%) and 5 
specificity (87%) were not high enough to replace AVS (27).  6 
The measurement of minor steroids (18-hydroxycorticosterone, 18OHB, 18-hydroxycortisol, 7 
18OHF and 18-oxo-cortisol, 18oxoF) in serum has also been proposed to distinguish PA subtypes 8 
(28-30). 18OHB is synthesized by aldosterone synthase from deoxycorticosterone as an 9 
intermediate during aldosterone biosynthesis (31) and is secreted at a higher rate in APA than BAH 10 
patients (28,29). 18OHF and 18oxoF, also known as “hybrid steroids”, are synthesized by 11 
aldosterone synthase from 11-deoxycortisol (32,33); these two steroids are also present at higher 12 
levels in APA than BAH (28,30), and at very high levels in some familial forms of PA (familial 13 
hyperaldosteronism type 1 and some families with type 3) (34). Recently, 18OHB, 18OHF and 14 
18oxoF have been measured in essential hypertensives and PA patients (35): despite their potential 15 
use in PA diagnosis and its subtypes (for example patients with very high values were all APA and 16 
with very low values were all essential hypertensives), such measurements need to be standardized 17 
and verified in a large population of hypertensives (35). Interestingly, measurement of 18oxoF and 18 
18OHB in the adrenal veins has been reported to be useful in subtype diagnosis of PA (36,37).  19 
Before performing AVS, familial hyperaldosteronism types I and III (34) should be considered and 20 
excluded at least in young PA patients and/or with a suggestive family history (34). 21 
 22 
Is it preferable to perform AVS with or without ACTH infusion? 23 
Cosyntropin [a synthetic derivative of the adrenocorticotropic hormone (ACTH) that contains only 24 
the first 24 of 39 amino acids of ACTH but retains full function, also called ACTH 1-24] infusion 25 
was introduced to AVS to improve its reliability (14). Cosyntropin constant infusion (50 g/hour, 26 
 8 
starting 30 minutes before the procedure) or bolus (usually 0.25mg = 10 IU) is used in many centres 1 
to minimize aldosterone fluctuations induced by procedure-associated stress, to maximize the 2 
cortisol gradient between the adrenal and peripheral veins and to maximize aldosterone production 3 
from the APA if present (20) (Panel 3). In contrast, cosyntropin infusion carries the potential pitfall 4 
of stimulating aldosterone secretion from the adrenal contralateral to the APA, resulting in a 5 
reduction of the lateralisation index (LI) (Table 1) (38). A recent multicentric study compared the 6 
role of both continuous cosyntropin infusion and bolus on the performance and interpretation of 7 
AVS (39). Both cosyntropin infusion and bolus resulted in a significant increase in the selectivity 8 
index (SI) (Table 1) whereas LI was not significantly affected. In most patients the diagnosis 9 
reached with AVS was the same whether unstimulated or cosyntropin infusion or bolus results were 10 
considered (39), when strict criteria for interpretation were used (see below). Although there are no 11 
studies that have specifically compared the two protocols of cosyntropin stimulation, continuous 12 
cosyntropin infusion is preferable to intravenous bolus because it avoids the fluctuation in 13 
aldosterone concentration but does not cause the supraphysiological stimulation of the bolus that 14 
may stimulate aldosterone production from the contralateral adrenal gland. In some centres, both 15 
basal and cosyntropin stimulated AVS are performed in each patient. Cosyntropin stimulation is 16 
necessary for those patients with a history of contrast allergy that require preparation with steroids 17 
before the procedure and when the procedure is not performed in the early morning when the 18 
ACTH secretion is maximal.  19 
 20 
Which adrenal/peripheral cortisol ratio is preferable to define successful cannulation? 21 
Selectivity index (SI) is defined as the ratio between the cortisol measured in the adrenal vein and in 22 
a peripheral vein (often the inferior vena cava) (Table 1). SI measures the adequacy of adrenal vein 23 
cannulation and therefore, has to be higher than 1 (Panel 4). However, there is no consensus on the 24 
ideal SI, with cut-offs between 1.1 and 3 under basal conditions (16,40) with most authors using an 25 
SI between 2 and 3 (41,42) and between 2 and 10 after cosyntropin stimulation (21) and most 26 
 9 
commonly between 3 and 5 (15,43,44). In a study performed in the Torino and Brisbane units, the 1 
reproducibility of the diagnosis between two AVS performed in the same patient under basal 2 
conditions, using different criteria, was evaluated (42). AVS in each patient was repeated because it 3 
was not considered successful the first time according to the unit criteria. The authors observed that 4 
a SI> 2.7 was necessary to achieve the reproducibility between AVS in the same patient (42). 5 
Evaluation of the procedures using SI<2 resulted in discordant diagnoses in a high proportion of 6 
cases and would result in the removal of the wrong adrenal in 14% of cases (42). The requirement 7 
of a high SI for diagnostic reproducibility was also seen in a study using high doses of continuous 8 
cosyntropin infusion (45). The use of a high SI for AVS interpretation is associated with a lower 9 
proportion of procedures that achieve a diagnosis: however, an increase in procedure success may 10 
be obtainable by other strategies (see below) rather than using lower SI cut-offs and thereby risking 11 
an incorrect diagnosis and inappropriate therapy.  12 
 13 
Which aldosterone/cortisol ratio (adrenal to contralateral or adrenal to peripheral) is 14 
preferable to define lateralisation? 15 
This is an important issue because the LI determines the final therapeutic decision for the patient, 16 
surgical with unilateral adrenalectomy or pharmacological with MRA. The ideal LI (Table 1) 17 
should be theoretically identified by evaluation of post-surgical improvement of blood pressure 18 
levels and biochemical cure of PA after adrenalectomy (43): in such a study all dominant adrenals 19 
(that is those with the higher aldosterone/cortisol ratio) should be removed regardless of the LI 20 
value. This type of study is obviously not feasible for ethical reasons and therefore the question 21 
remains unresolved. Most centres require LI > 4 to indicate unilateral adrenalectomy, but many 22 
centres accept an LI between 3 and 4 and a few centres use a LI between 2 and 3 (Panel 4); finally 23 
one centre does not use a LI but requires an ipsilateral ratio (ILR) > 2 (Table 1) together with a 24 
contralateral ratio (CLR) < 1 (Table 1) to diagnose unilateral PA (14). It is conceivable that LI > 4 25 
are definitively diagnostic of unilateral PA and LI<2 are consistent with bilateral PA, with 26 
 10 
intermediate values representing a grey zone between the two conditions: in such cases, other 1 
clinical, biochemical and AVS findings (such as CLR and ILR) can be used to reach a therapeutic 2 
decision in the single patient (46). Some authors evaluate absolute aldosterone levels, that if higher 3 
than 1,400 ng/dL in one adrenal vein, suggest aldosterone hypersecretion from that side (17). 4 
However, we recommend to always take into account the cortisol corrected ratios, because the 5 
contralateral adrenal could also secrete very high aldosterone levels and a non-selective cannulation 6 
would result in a false diagnosis of unilateral PA. 7 
 8 
Is contralateral “suppression” necessary? 9 
Contralateral suppression defines patients that on AVS show an aldosterone to cortisol ratio in the 10 
non-dominant adrenal less than the ratio in the peripheral vein sample (Table 1). Some units have 11 
suggested that contralateral suppression might identify the source of aldosterone hyperproduction 12 
when only one adrenal vein is able to be accessed (43,46) (Panel 4): however, there is agreement 13 
that the CLR cannot be relied on to predict unilateral PA by itself, since up to 30% of BAH patients 14 
display CLR <1 (15). It is not known if the presence of CLR<1 should be a prerequisite for 15 
recommending adrenalectomy since it has not been systematically evaluated in terms of outcome. 16 
For instance, a few centres use it to define the diagnosis of unilateral PA together with an ipsilateral 17 
ratio (ILR) >2 (Table 1) (16). 18 
The concept of CL suppression does not reflect a complete suppression of aldosterone secretion in 19 
the contralateral gland: in fact, the aldosterone levels measured from the contralateral adrenal gland 20 
to an APA are usually higher than aldosterone levels in a peripheral vein. It should be noted that in 21 
most cases peripheral blood is expected to have low aldosterone/cortisol ratios, given the longer 22 
half-life of cortisol when compared to aldosterone. The fact that the aldosterone hyperproduction 23 
from an APA is not sufficient to completely inhibit aldosterone production from the “normal” 24 
adrenal cortex has been reinforced by the observation that the zona glomerulosa surrounding an 25 
APA is often hyperplastic, containing nodules that may express aldosterone synthase (47). These 26 
 11 
observations recall the findings that rats under long-term high sodium diets display a reduction in 1 
the size of the zona glomerulosa, but always show nests of cells with high aldosterone synthase 2 
expression levels (48). For this reason some authors have hypothesized that a proportion of PA 3 
patients with unilateral adrenal disease are in reality affected by BAH in which a nodule 4 
subsequently became dominant analogous to a multinodular thyroid goiter (49,50). However, 5 
several studies have demonstrated recently that somatic mutations in different genes (KCNJ5, 6 
ATP1A1, ATP2B3 and CACNA1D) are present in APAs, but not in BAH patients (34,51-54). Some 7 
authors observed an effect of the mutational status of the APA on LI (55) whereas in other cohort 8 
this was not the case (56). 9 
 10 
How can success rates of AVS in centres with limited experience be improved? 11 
For AVS to be more widely used it is crucial that centres with non-expert radiologists improve the 12 
rate of successful, and therefore diagnostic, procedures. The first and fundamental issue is the 13 
training of one or at most two motivated radiologists who perform all the procedures: it has been 14 
shown that centres having more radiologists performing AVS have much lower success rates than 15 
centres with a single expert radiologist (15,16,19,20,22,42,44,57). AVS success increases with the 16 
standardization of the protocol and with experience: wherever possible, procedures should be 17 
concentrated in a single centre per geographical area to increase the number of AVS per year. It is 18 
also important that all AVS results are discussed together by the specialists involved in the patient’s 19 
management (hypertension specialist/endocrinologist and radiologist) and that the clinician 20 
consulted attends the radiological procedure (41). This feed-back and encouragement between 21 
physicians clearly contributes to an increase in AVS success rate.  22 
Centres that perform AVS should generate a standardized AVS report including all measurements, a 23 
statement of final PA subtype diagnosis and a recommendation regarding treatment (Panel 5). The 24 
use of a specified protocol in each centre is a fundamental requirement while waiting for a 25 
universally accepted and standardized protocol to be used in all centres. A recent study showed that 26 
 12 
the use of cosyntropin infusion resulted in a higher number of AVS with diagnostic results 1 
compared to the unstimulated procedure (39). Therefore, AVS with cosyntropin infusion should be 2 
considered together with or in alternative to the basal procedure in units with a low success rate or 3 
limited experience. Finally, and more importantly, many studies have shown the fundamental role 4 
of the rapid cortisol assay during AVS (41,58-60). Cortisol is measured immediately after sampling 5 
from each site and results are given in a short time (less than 20 minutes) allowing an almost 6 
immediate feed-back on the success of the procedure. Most units that employ the intraprocedural 7 
cortisol assay, measure the hormone at the central laboratory of the hospital (41,59,61) usually 8 
using an immunochemiluminometric assay (41,61); in the Torino unit, the use of a quick and 9 
reliable cortisol immunofluorimetric assay method that can be performed inside the radiology room 10 
using a benchtop analyzer and provides the radiologist with almost immediate information on the 11 
correct positioning of the catheter tip for sampling, and reduces the timing and risk of confusion in 12 
tube handling (58). All rapid cortisol measurements have the advantage of allowing the radiologist 13 
further attempts at cannulation until cortisol measurements demonstrate sampling success. This has 14 
an impact both on self-training of the radiologist and in reducing the number of unsuccessful 15 
procedures (41,58-61). 16 
 17 
Unresolved issues 18 
Over the last decade many studies have helped clarify AVS protocol and interpretation; a number of 19 
unresolved issues remain. One is the simultaneous as opposed to sequential adrenal vein 20 
cannulation. Simultaneous cannulation has the potential advantage of avoiding oscillations of 21 
aldosterone secretion during the procedure, and the disadvantage of making AVS even more 22 
difficult and demanding. In our experience the variations in aldosterone and cortisol production 23 
during the procedure are minimal if AVS is relatively rapid and uncomplicated. Another issue is the 24 
interpretation of AVS in cases in which the APA co-secretes a variable amount of cortisol (62). The 25 
simultaneous cosecretion of aldosterone and cortisol from the APA may cause a reduction of LI and 26 
 13 
result in the diagnosis of bilateral PA. The presence of an APA that cosecretes cortisol has been 1 
found to be rare in an Italian study (62) but more frequent in the Japanese population (63). It seems 2 
that this occurrence is more frequent when the adenoma is large in size (64): for this reason we 3 
suggest performing an overnight 1 mg dexamethasone suppression test in patients with a suspect 4 
APA larger than 10 mm before AVS; if positive, the procedure should be performed during 5 
cosyntropin infusion. Alternatively, plasma metanephrine rather than cortisol might be used to 6 
correct for blood dilution during AVS (65). 7 
Another issue is the interpretation of AVS with an aldosterone/cortisol ratio in both adrenal veins 8 
that is lower than that measured in a peripheral vein: a recent study showed that repetition of the 9 
procedure show half of the patients have a unilateral PA (66); it is not known if the performance of 10 
the procedure under cosyntropin infusion could avoid repetition of the AVS. 11 
Finally, it has been shown recently that it is possible to perform a super-selective cannulation of the 12 
adrenal branches: this technique could be potentially applied during AVS in patients with adrenals 13 
that cosecrete aldosterone and cortisol from different nodules, to distinguish BAH from bilateral 14 
APAs, and in those (rare) patients who are candidates for partial adrenalectomy (67,68). At present 15 
it is unknown if this technique is associated with a higher rate of complications than the usual 16 
procedure. 17 
AVS cut-offs are destined to be arbitrary and difficult to be prospectively tested in most cases. 18 
Therefore, AVS consensus guidelines are necessary and should consider all relevant information 19 
concerning a patient to obtain the best diagnosis and treatment. 20 
Recently, a consensus statement was published by other authors that has some common 21 
recommendations with our manuscript and some differences. The differences include the impact of 22 
the stress on the final diagnosis, the importance of the simultaneous cannulation in unstimulated 23 
procedures, the role of cosyntropin stimulation and the cut-off level of SI and LI (69).  24 
 25 
Conclusions 26 
 14 
Following the publication of the first Endocrine Society Guidelines for the diagnosis and treatment 1 
of PA, it has become increasingly appreciated that PA is a frequent condition and therefore a 2 
significantly large number of hypertensive subjects now undergo screening and 3 
confirmatory/exclusion testing. AVS has undoubtedly been proven to be the only reliable means for 4 
PA subtype diagnosis to direct patients to surgery or medical treatment. The training of dedicated 5 
radiologists and the use of standardized protocols for the performance and interpretation of AVS, 6 
including the use of higher SI and LI for interpretation of the results and the use of an 7 
intraprocedural rapid cortisol assay, results in robust PA subtype diagnosis and may improves the 8 
therapeutic management of this disease. 9 
Legend to figure 1. 10 
Schematic description of adrenal vein anatomy and adrenal vein sampling performance.  11 
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Panel 1 30 
Selection and preparation of the patients for AVS 31 
● AVS only for patients with confirmed PA and after CT scan 32 
●Rule out familial hyperaldosteronism type I and III 33 
●Rule out subclinical hypercortisolism for APA>10 mm 34 
●Have a defined standardized protocol 35 
●Withdraw interfering medication ( especially diuretics and MRA) 36 
and/or have PRA<1 ng/ml/h (or PRC < 20 U/ml) 37 
●At least 1 h recumbency before beginning of the procedure 38 
●Measure cortisol and aldosterone in each sample 39 
●Take a sample for cortisol and aldosterone assay from a 40 
peripheral vein every time an adrenal vein is sampled 41 
 42 
Panel 2 43 
Patients that could avoid AVS 44 
●If <40 y.o., with unilateral APA>10mm and normal 45 
contralateral adrenal 46 
●Positive 11C-metomidate PET-CT and no AVS available 47 
● Severe clinical phenotype, including high aldosterone and  48 
 hypokalemia, unilateral lesions on CT, FH1 and 3  49 
 excluded and AVS unavailable on site or by referral 50 
 51 
Panel 3 52 
 20 
Use of cosyntropin infusion 1 
●Increases SI and success rate of cannulation of the adrenal veins 2 
●Does not change LI and final diagnosis 3 
●Avoids potential fluctuation in aldosterone secretion 4 
●Is necessary for the allergic patient undergoing steroid  5 
 treatment before the procedure 6 
●Is necessary when the procedure is not performed  7 
 in the early morning 8 
●If AVS is perfomed without cosyntropin, collect simultaneous  9 
 peripheral samples in sequential AVS or perform  10 
 simultaneous bilateral AVS 11 
 12 
Panel 4 13 
Role of SI, LI and CLR 14 
●SI expresses the correct cannulation of the adrenal veins 15 
●SI should be > 3 under basal conditions  16 
 and > 5 under cosyntropin  17 
●AVS with SI <2 (basal) or <3 (cosyntropin) should  18 
 be discarded as not diagnostic 19 
●No LI have been validated in prospective trials 20 
●LI > 4 are considered diagnostic for unilateral PA 21 
●LI< 3 are considered diagnostic for bilateral PA 22 
●For intermediate values, clinical and biochemical 23 
 factors are used for final decision 24 
●Contralateral suppression is defined by CLR<1 25 
●Relevance for adrenalectomy indication unknown 26 
●Useful for interpretation of suboptimal AVS studies 27 
 28 
 29 
Panel 5 30 
Use of standardised AVS report 31 
●report aldosterone concentration, cortisol concentration and  32 
 aldosterone/cortisol ratio for  each collected sample 33 
●the minimum data set comprises right adrenal vein, left adrenal  34 
 vein, and inferior vena cava sample 35 
●calculate and report SI including centre-specific cut-offs 36 
●calculate and report LI including centre-specific cut-offs 37 
●calculate and report CLR 38 
●generate a statement regarding PA subtype and a  39 
 recommendation regarding treatment 40 
 41 
 42 
 43 
 44 
 45 
AVS Indices Measurement Clinical significance Suggested Cut-off 
 
Selectivity Index 
(SI) 
 
Cortisoladrenal vein  
Cortisolperipheral vein 
 
Adequacy of 
cannulation of the 
adrenal veins 
Minimal requirement 
of SI>2 under basal 
conditions, SI>3 
during cosyntropin 
(>3 and >5 
 21 
respectively are 
preferable) 
 
Lateralisation 
Index (LI) 
 
Aldosterone/Cortisoladrenal vein 
                                                                                                                 
Aldosterone/Cortisolcontralateral 
adrenal vein 
 
Lateralisation of 
aldosterone
production. To 
distinguish between 
unilateral and 
bilateral PA 
LI > 4 indicates 
unilateral PA; LI<3 
indicates bilateral 
PA; 3<LI<4 is a grey 
zone  
Contralateral ratio 
(CLR) 
 
Aldosterone/Cortisolnondominant 
adrenal vein     
                                                                                                       
Aldosterone/ Cortisolperipheral 
vein  
 
Inhibition of 
aldosterone secretion 
in the non-dominant 
adrenal gland  
CLR<1 confirms 
unilateral PA in the 
opposite side; can be 
used when the other 
adrenal vein is not 
cannulated or when 
LI is in the grey zone 
 
Ipsilateral Ratio 
(ILR) 
 
Aldosterone/Cortisoldominant 
adrenal vein 
 
Aldosterone/Cortisol peripheral 
vein 
 
 
Gradient between the 
dominant adrenal and 
the peripheral vein 
ILR >2 is required 
together with CLR<1 
in some centres to 
diagnose unilateral 
PA 
 1 
Table 1. AVS indices, definition and clinical significance and cut-offs in the clinical setting. 2 
 3 
 4 
 22 
 1 
